Form 8-K - Current report:
SEC Accession No. 0000950170-25-023729
Filing Date
2025-02-20
Accepted
2025-02-20 07:00:08
Documents
13
Period of Report
2025-02-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fgen-20250219.htm   iXBRL 8-K 61306
2 EX-99.1 fgen-ex99_1.htm EX-99.1 22866
3 GRAPHIC img3914235_0.jpg GRAPHIC 10772
  Complete submission text file 0000950170-25-023729.txt   221702

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fgen-20250219.xsd EX-101.SCH 24862
15 EXTRACTED XBRL INSTANCE DOCUMENT fgen-20250219_htm.xml XML 4696
Mailing Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133
Business Address 350 BAY STREET SUITE 100 #6009 SAN FRANCISCO CA 94133 415-978-1200
FIBROGEN INC (Filer) CIK: 0000921299 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36740 | Film No.: 25643217
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)